SUNNYVALE, Calif.--(BUSINESS WIRE)--Elixir Medical Corporation, a developer of products that combine state-of-the-art medical devices with advanced pharmaceuticals, announced six-month randomized clinical trial results today demonstrating the superiority of the Elixir DESyne™ BD Novolimus Eluting Coronary Stent System compared to the control Endeavor® Zotarolimus Eluting Coronary Stent System in the primary endpoint of in-stent late lumen loss and the secondary endpoint of binary restenosis.
